The embodiments disclose a process for manufacturing a sensor including depositing a first conductive layer on a substrate followed by curing the first conductive layer and, depositing a temperature controlling conductive ink on top of a portion of the first conductive layer followed by curing the temperature controlling conductive ink and, depositing an insulating layer on top of the temperature controlling conductive ink layer and a portion of the first conductive layer followed by curing the insulating layer and, depositing a second conductive layer on top of a portion of first conductive layer followed by curing the second conductive layer and, depositing an adhesive layer on top of a portion of the first conductive layer for adhering a memory chip to the first conductive layer followed by curing the adhesive layer and, depositing at least one biomolecule layer on top of the second conductive layer followed by drying the at least one biomolecule layer.

This invention provides methods for detecting viruses, viral antigens, viral antibodies, and other antigens and antibodies using single molecule electronic nanopores and polymer tags.

The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.

The present invention relates to a method for detecting a pathogen in cellular lysate by measuring pathogen-specific enzyme activity. The method comprises contacting the cellular lysate with a substrate the pathogen of interest recognizes and modifies, and obtaining a measurable, recordable, signal. The method may comprise detection of SARS-CoV viruses using the activity of SARS PLpro enzyme in tongue scrape lysate as a readout.

A recombinant polypeptide can be used in the diagnosis of the presence of a Zika virus in a patient. The recombinant polypeptide includes SEQ ID NO: 1 or a variant thereof. The recombinant peptide may be a monomer, a dimer, or a hexamer.

The present invention is directed to an artificial nucleic acid, particularly to an artificial RNA, and to polypeptides suitable for use in treatment or prophylaxis of an infection with a virus of the order Bunyavirales, particularly Severe fever with thrombocytopenia syndrome virus (SFTSV), Rift Valley fever virus (RVFV), or Crimean-Congo hemorrhagic fever virus (CCHFV), or a disorder related to such an infection. The present invention further concerns a Bunyavirales vaccine, particularly a SFTSV, RVFV, or CCHFV vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

In a first aspect, the present invention relates to a method for determining the responsiveness of an individual to vaccination, like viral vaccination or for the determination of viral vaccine efficacy in an individual as well as a method for the stratification of the vaccination regimen, e.g. viral vaccination, in an individual based on determining the level or the amount of at least one of IL-8 or IL-18 in a sample; said sample is obtained from an individual at least once before or at least once after vaccination. The method allows to determine the vaccination regimen with the vaccine, in particular, a virus vaccine, like an influenza virus vaccine whereby when a low level of at least one of IL-8 and/or IL-18 is determined, said low level is indicative for a personalized vaccine strategy. In a further aspect, the use of at least one of IL-8 or IL-18 as a predictive marker for vaccine efficacy or immune protection by vaccination is provided. Finally, a kit of parts for vaccination comprising equipment for determining the level and/or amount of at least one of IL-8 or IL-18 in a sample obtained from an individual to be vaccinated as well as the vaccine to be administered is described.

Methods are provided for determining the presence of a first ligand in a sample. In some embodiments depletion conjugates are used to deplete the ligands different from but related to the first ligands from the sample. In some embodiments, interim binding agents are used to enhance the test signal.

Provided is a dimer antibody including two structural domains independently each represented by the following amino acid sequence, in an N- to C-direction, N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-C
wherein the antibody is capable of binding to a norovirus; FR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence; any one of the following requirements (i)-(iii) is satisfied. Requirement (i): the CDR1 includes an amino acid sequence having a sequence identity of not less than 60% with any one of the amino acid sequences represented by SEQ ID NO: 1-SEQ ID NO: 6, the CDR2 includes an amino acid sequence having a sequence identity of not less than 60% with any one of the amino acid sequences represented by SEQ ID NO: 7-SEQ ID NO: 12, and the CDR3 includes an amino acid sequence having a sequence identity of not less than 60% with any one of the amino acid sequences represented by SEQ ID NO: 13-SEQ ID NO: 17; Requirement (ii): the CDR1 includes an amino acid sequence in which one-three amino acid(s) of any one of the amino acid sequence represented by SEQ ID NO: 1-SEQ ID NO: 6 has/have been substituted, deleted, or added, the CDR2 includes an amino acid sequence in which one-three amino acid(s) of any one of the amino acid sequence represented by SEQ ID NO: 7-SEQ ID NO: 12 has/have been substituted, deleted, or added, and the CDR3 includes an amino acid sequence in which one-three amino acid(s) of any one of the amino acid sequence represented by SEQ ID NO: 13-SEQ ID NO: 17 has/have been substituted, deleted, or added; and Requirement (iii): the CDR1 includes any one of the amino acid sequence represented by SEQ ID NO: 1-SEQ ID NO: 6, the CDR2 includes any one of the amino acid sequence represented by SEQ ID NO: 7-SEQ ID NO: 13, and the CDR3 includes any one of the amino acid sequence represented by SEQ ID NO: 13-SEQ ID NO: 17.

The present invention provides soluble truncated peptides of CDHR3, recombinant variants thereof and methods of making these peptides. The present invention also provide methods of inhibiting rhinovirus C infection and an in vitro assay for screening for anti-viral agents against rhinovirus C.